Patents Assigned to Sangamo Therapeutics, Inc.
  • Compositions and methods for producing recombinant AAV
    Patent number: 11718834
    Abstract: Provided herein are nucleic acid constructs, host insect cells, and methods for producing recombinant AAV capsids with high potency at high yield.
    Type: Grant
    Filed: February 14, 2020
    Date of Patent: August 8, 2023
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Andrea J. Kang, Richard T. Surosky, Alex Michael Ward
  • ZINC FINGER PROTEIN TRANSCRIPTION FACTORS FOR REPRESSING TAU EXPRESSION
    Publication number: 20230242602
    Abstract: The present disclosure provides zinc finger fusion proteins that inhibit expression of tau in the nervous system, and methods of using the proteins to treat neurodegenerative diseases such as Alzheimer's disease, frontotemporal dementia, and other tauopathies.
    Type: Application
    Filed: January 22, 2021
    Publication date: August 3, 2023
    Applicant: Sangamo Therapeutics, Inc.
    Inventors: Bryan Zeitler, Asa Hatami, Lei Zhang
  • Delivery of target specific nucleases
    Patent number: 11690921
    Abstract: Described herein are lipid nanoparticles comprising cationic lipids and other lipids and also comprising engineered nucleases facilitate transfer of nucleic acids to cells.
    Type: Grant
    Filed: May 15, 2019
    Date of Patent: July 4, 2023
    Assignees: Sangamo Therapeutics, Inc., Life Technologies Corporation
    Inventors: Anthony Conway, Xavier de Mollerat du Jeu, Shikha Mishra
  • DNA-binding proteins and uses thereof
    Patent number: 11661612
    Abstract: Disclosed herein are polypeptides, polynucleotides encoding, cells and organisms comprising novel DNA-binding domains, including TALE DNA-binding domains. Also disclosed are methods of using these novel DNA-binding domains for modulation of gene expression and/or genomic editing of endogenous cellular sequences.
    Type: Grant
    Filed: February 12, 2019
    Date of Patent: May 30, 2023
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Philip D. Gregory, Jeffrey C. Miller, David Paschon, Edward J. Rebar, Siyuan Tan, Fyodor Urnov, Lei Zhang
  • Genetic modification of cytokine inducible SH2-containing protein (CISH) gene
    Patent number: 11661611
    Abstract: The present disclosure is in the field of genome engineering, particularly targeted genetic modification of a CISH gene.
    Type: Grant
    Filed: November 9, 2018
    Date of Patent: May 30, 2023
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Anthony Conway, Gary K. Lee
  • Methods and compositions for modification of a cystic fibrosis transmembrane conductance regulator (CFTR) gene
    Patent number: 11655275
    Abstract: Nucleases and methods of using these nucleases for alteration of a CFTR gene and generation of cells and animal models.
    Type: Grant
    Filed: May 2, 2018
    Date of Patent: May 23, 2023
    Assignee: Sangamo Therapeutics, Inc.
    Inventor: Anthony Conway
  • Methods and compositions for gene inactivation
    Patent number: 11648267
    Abstract: Disclosed herein are methods and compositions for inactivating CCR-5 genes, using zinc finger nucleases (ZFNs) comprising a zinc finger protein and a cleavage domain or cleavage half-domain. Polynucleotides encoding ZFNs, vectors comprising polynucleotides encoding ZFNs, such as adenovirus (Ad) vectors, and cells comprising polynucleotides encoding ZFNs and/or cells comprising ZFNs are also provided.
    Type: Grant
    Filed: July 3, 2018
    Date of Patent: May 16, 2023
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Dale Ando, Michael C. Holmes, Gary Ka Leong Lee
  • Targeted integration into the PPP1R12C locus
    Patent number: 11649468
    Abstract: Disclosed herein are methods and compositions for targeted integration of an exogenous sequence into the human PPP1R12C locus, for example, for expression of a polypeptide of interest.
    Type: Grant
    Filed: January 25, 2018
    Date of Patent: May 16, 2023
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Russell DeKeiver, Philip D. Gregory, David Paschon, Phillip Tam, Fyodor Urnov
  • Methods and compositions for regulation of transgene expression
    Patent number: 11639504
    Abstract: Nucleases and methods of using these nucleases for expressing a transgene from a safe harbor locus in a secretory tissue, and clones and animals derived therefrom.
    Type: Grant
    Filed: April 3, 2019
    Date of Patent: May 2, 2023
    Assignee: Sangamo Therapeutics, Inc.
    Inventor: Edward J. Rebar
  • Methods and compositions for treating hemophilia
    Patent number: 11634463
    Abstract: Disclosed herein are methods and compositions for insertion of transgene sequences encoding proteins involved in clotting into the genome of a cell for treating conditions including hemophilias.
    Type: Grant
    Filed: July 26, 2019
    Date of Patent: April 25, 2023
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Jeffrey C. Miller, David Paschon, Edward J. Rebar
  • LIVER-SPECIFIC CONSTRUCTS, FACTOR VIII EXPRESSION CASSETTES AND METHODS OF USE THEREOF
    Publication number: 20230119850
    Abstract: Described herein are constructs used for liver-specific expression of a transgene.
    Type: Application
    Filed: September 1, 2022
    Publication date: April 20, 2023
    Applicant: Sangamo Therapeutics, Inc.
    Inventors: Brigit E. Riley, Gary K. Lee
  • Compositions for linking DNA-binding domains and cleavage domains
    Patent number: 11608492
    Abstract: Disclosed herein are compositions for linking DNA binding domains and cleavage domains (or cleavage half-domains) to form non-naturally occurring nucleases. Also described are methods of making and using compositions comprising these linkers.
    Type: Grant
    Filed: September 28, 2020
    Date of Patent: March 21, 2023
    Assignee: Sangamo Therapeutics, Inc.
    Inventor: Jeffrey C. Miller
  • Method of making and using mammalian liver cells for treating hemophilia or lysosomal storage disorder
    Patent number: 11591622
    Abstract: Disclosed herein are methods and compositions for targeted, nuclease-mediated insertion of transgene sequences into the genome of a cell.
    Type: Grant
    Filed: August 5, 2019
    Date of Patent: February 28, 2023
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Michael C. Holmes, Thomas Wechsler
  • NOVEL COMPOSITIONS AND METHODS FOR PRODUCING RECOMBINANT AAV
    Publication number: 20230020565
    Abstract: Provided herein are nucleic acid constructs, host insect cells, and methods for producing recombinant AAV capsids with high potency at high yield.
    Type: Application
    Filed: December 4, 2020
    Publication date: January 19, 2023
    Applicant: Sangamo Therapeutics, Inc.
    Inventors: Alex Michael Ward, Hung Tran, Andrea J. Kang, Tzu-Hung Chen, Richard T. Surosky
  • Zinc Finger Protein Transcription Factors for Treatment of Prion Disease
    Publication number: 20230002459
    Abstract: The present disclosure provides zinc finger fusion proteins that inhibit expression of the prion gene in the nervous system, and methods of using the proteins to treat prion disease.
    Type: Application
    Filed: October 2, 2020
    Publication date: January 5, 2023
    Applicant: Sangamo Therapeutics, Inc.
    Inventors: Bryan Zeitler, Lei Zhang
  • GENERATION OF ENGINEERED REGULATORY T CELLS
    Publication number: 20220380727
    Abstract: Provided herein are genetically engineered mammalian stem and progenitor cells that have increased potential to differentiate into regulatory T cells. Also provided are methods of making and use thereof.
    Type: Application
    Filed: November 9, 2020
    Publication date: December 1, 2022
    Applicant: Sangamo Therapeutics, Inc.
    Inventors: Anthony Conway, Helen Fong, George Kwong
  • Targeted disruption of T cell and/or HLA receptors
    Patent number: 11512287
    Abstract: Disclosed herein are methods and compositions for inactivating TCR and/or HLA genes, using engineered nucleases comprising at least one DNA binding domain and a cleavage domain or cleavage half-domain in conditions able to preserve cell viability. Polynucleotides encoding nucleases, vectors comprising polynucleotides encoding nucleases and cells comprising polynucleotides encoding nucleases and/or cells comprising nucleases are also provided.
    Type: Grant
    Filed: June 15, 2018
    Date of Patent: November 29, 2022
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Anthony Conway, Sumiti Jain, Gary K. Lee, David Paschon, Edward J. Rebar, Lei Zhang
  • Tau modulators and methods and compositions for delivery thereof
    Patent number: 11504389
    Abstract: The present disclosure is in the field of diagnostics and therapeutics for Alzheimer's Disease.
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: November 22, 2022
    Assignees: Sangamo Therapeutics, Inc., The General Hospital Corporation
    Inventors: Annemarie Ledeboer, Bryan Zeitler, H. Steve Zhang, Sarah DeVos, Bradley T. Hyman, Susanne Wegmann
  • Methods and compositions for treatment of a genetic condition
    Patent number: 11492643
    Abstract: Methods and compositions for a genetic disease are provided.
    Type: Grant
    Filed: April 2, 2018
    Date of Patent: November 8, 2022
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Gregory J. Cost, Philip D. Gregory, Dmitry Guschin, Michael C. Holmes, Jeffrey C. Miller, David Paschon, Edward J. Rebar, Andreas Reik, Fyodor Urnov, Lei Zhang
  • Zinc Finger Protein Transcription Factors for Repressing Alpha-Synuclein Expression
    Publication number: 20220324928
    Abstract: The present disclosure provides zinc finger fusion proteins that inhibit expression of alpha-synuclein in the nervous system, and methods of using the proteins to treat Parkinson's disease, Lewy body dementia, multiple system atrophy, Alzheimer's disease, and other neurodegenerative diseases.
    Type: Application
    Filed: October 2, 2020
    Publication date: October 13, 2022
    Applicant: Sangamo Therapeutics, Inc.
    Inventors: Asa Hatami, Bryan Zeitler, Lei Zhang, David Emanuel Paschon